Treating hemophilia and other blood disorders

Carter Haydu
Send to a friend

Send this article to a friend.

Dr. Walid Shammas

“What is the future? I think that’s the question everyone asks,” said Baxter BioScience medical science liaison Dr. Walid Shammas, who was the first speaker on Saturday’s installment of the Hemophilia Saskatchewan “Back to the Future” Family Weekend at Prairie Oasis.

During his presentation to about 60 participants in the weekend gathering, Shammas said his company, which is the first Canadian company to hemophilia treatment development, is focusing on multiple areas of research towards treating blood disorder.

For example, the company is trying to broaden the number of components that come into the market, as well as extend the effectiveness of current products on the patient.

“Perhaps we can use them less often and have the same results,” he said, adding Baxter is also trying to develop alternate routes for delivery of medication, as well as inhibit preventatives to medication working.

For more on this story, read an upcoming edition of the Times-Herald.

Organizations: Baxter, Times-Herald

  • 1
  • 2
  • 3
  • 4
  • 5

Thanks for voting!

Top of page